NCT00920686 is a Phase 2 clinical trial of NXN-188 in Migraine With Aura, sponsored by NeurAxon Inc..

Who is sponsoring NCT00920686?

NCT00920686 is sponsored by NeurAxon Inc..

What drugs are being tested in NCT00920686?

Interventions in NCT00920686: NXN-188, placebo, sumatriptan succinate.

What condition does NCT00920686 study?

NCT00920686 studies Migraine With Aura.

Is NCT00920686 still recruiting?

NCT00920686 is currently completed. Last updated 20 July 2014.

Are results published for NCT00920686?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-07-20 · How we verify

NCT00920686

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura

Completed Phase 2 Results posted Last updated 20 July 2014

What this trial tests

Phase 2 trial testing NXN-188 in Migraine With Aura in 239 participants. Completed in 1 March 2010.

Timeline

1 June 2009

Primary endpoint
1 March 2010

1 March 2010

Quick facts

Lead sponsor	NeurAxon Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	239
Start date	1 June 2009
Primary completion	1 March 2010
Estimated completion	1 March 2010
Sites	16 locations across United States

Drugs / interventions tested

NXN-188 — full drug profile →
placebo
sumatriptan succinate — full drug profile →

Conditions studied

Migraine With Aura — all drugs for Migraine With Aura →

Sponsor

NeurAxon Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Migraine With Aura. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time (Hours) to First Use of Rescue Medication
Time frame: 24 hours

Sponsor's own description

NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted Nitric Oxide Synthase Inhibitors for Migraine.
Pradhan AA, Bertels Z, Akerman S. · · 2018 · cited 98× · PMID 29516436 · DOI 10.1007/s13311-018-0614-7

Verify or expand the search:

Other recruiting trials for Migraine With Aura

Currently open trials in the same condition.

NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
NCT05889624 — Responding With Evidence and Access for Childhood Headaches · NA · recruiting
NCT05903027 — Gepant treAtments: EffectIveNess and tolERability (GAINER) · recruiting
NCT05484349 — TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME） · Phase 3 · recruiting
NCT04715685 — Mind Body Balance for Pediatric Migraine · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00920686 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NeurAxon Inc.
Last refreshed: 20 July 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00920686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing